Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: Significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs

British Journal of Haematology

Volumn 164, Issue 1, 2014, Pages 113-123

  Milone, Giuseppe ^a,b   Martino, Massimo ^c   Spadaro, Andrea ^a   Leotta, Salvatore ^a   Di Marco, Annalia ^a   Scalzulli, Potito ^d   Cupri, Alessandra ^a   Di Martina, Valentina ^a   Schinocca, Elena ^a   Spina, Eleonora ^a   Tripepi, Giovanni ^e  

^a UNIVERSITY OF CATANIA   (Italy)

^b Istituto Oncologico del Mediterraneo   (Italy)

^c Ospedali Melacrino Morelli   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Apheresis harvest; Peripheral blood stem cell mobilization; Plerixafor

Indexed keywords

CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; ECONOMIC EVALUATION; EVENING DOSAGE; FEMALE; HEALTH CARE COST; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALVAGE THERAPY; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; TREATMENT FAILURE; YOUNG ADULT;

APHERESIS HARVEST; PERIPHERAL BLOOD STEM CELL MOBILIZATION; PLERIXAFOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84889583837     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12606     Document Type: Article

References (33)

1. Abhyankar, S., DeJarnette, S., Aljitawi, O., Ganguly, S., Merkel, D. & McGuirk, J. (2012) Arisk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of Plerixafor. Bone Marrow Transplantation, 47, 483-487.
2. Attolico, I., Pavone, V., Ostuni, A., Rossini, B., Musso, M., Crescimanno, A., Martino, M., Iacopino, P., Milone, G., Tedeschi, P., Coluzzi, S., Nuccorini, R., Pascale, S., Di Nardo, E. & Olivieri, A. (2012) Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biology of Blood and Marrow Transplantation, 18, 241-249.
3. Chabannon, C., Le Corroller, A.G., Viret, F., Eillen, C., Faucher, C., Moatti, J.P., Viens, P., Vey, N., Braud, A.C., Novakovitch, G., Ladaique, P., Stoppa, A.M., Camerlo, J., Genre, D., Maraninchi, D. & Blaise, D. (2003) Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dosechemotherapy and autologous hematopoietic cell transplantation. Leukemia, 17, 811-820.
4. Chen, A.I., Bains, T., Murray, S., Knight, R., Shoop, K., Bubalo, J., Fowler, C., Slater, S. & Maziarz, R.T. (2012) Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. Bone Marrow Transplantation, 47, 1526-1529.
5. Costa, L.J., Alexander, E.T., Hogan, K.R., Schaub, C., Fouts, T.V. & Stuart, R.K. (2011) Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplantation, 46, 64-69.
6. Cuzick, J. (2005) Forest plots and the interpretation of subgroups. Lancet, 365, 1308.
7. D'Addio, A., Curti, A., Worel, N., Douglas, K., Motta, M.R., Rizzi, S., Dan, E., Taioli, S., Giudice, V., Agis, H., Kopetzky, G., Soutar, R., Casadei, B., Baccarani, M. & Lemoli, R.M. (2011) The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplantation, 46, 356-363.
8. DiPersio, J.F., Stadtmauer, E.A., Nademanee, A., Micallef, I.N., Stiff, P.J., Kaufman, J.L., Maziarz, R.T., Hosing, C., Früehauf, S., Horwitz, M., Cooper, D., Bridger, G. & Calandra, G. (2009a) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood, 113, 5720-5726.
9. DiPersio, J.F., Micallef, I.N., Stiff, P.J., Bolwell, B.J., Maziarz, R.T., Jacobsen, E., Nademanee, A., McCarty, J., Bridger, G. & Calandra, G. (2009b) Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology, 27, 4767-4773.
10. Farina, L., Spina, F., Guidetti, A., Longoni, P., Ravagnani, F., Dodero, A., Montefusco, V., Carlo-Stella, C. & Corradini, P. (2013) Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte colony-stimulating factor: an algorithm for the pre-emptive use of Plerixafor. Leukemia and Lymphoma, doi: 10.3109/10428194.2013.802783.
11. Gazitt, Y., Callander, N., Freytes, C.O., Shaughnessy, P., Liu, Q., Tsai, T.W. & Devore, P. (2000) Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. Journal Hematotherapy and Stem Cell Research, 9, 737-748.
12. Horwitz, M.E., Chute, J.P., Gasparetto, C., Long, G.D., McDonald, C., Morris, A., Rizzieri, D.A., Sullivan, K.M. & Chao, N.J. (2012a) Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplantation, 47, 1051-1055.
13. Horwitz, M.E., Long, G., Holman, P., Libby, E., Calandra, G.C. & Schriber, J.R. (2012b) Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors. Bone Marrow Transplantation, 47, 1283-1286.
14. Hosing, C., Saliba, R.M., Ahlawat, S., Korbling, M., Kebriaei, P., Alousi, A., De Lima, M., Okoroji, J.G., McMannis, J., Qazilbash, M., Anderlini, P., Giralt, S., Champlin, R.E., Khouri, I. & Popat, U. (2009) Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. American Journal of Hematology, 84, 335-337.
15. Keating, G. (2011) Plerixafor a review of its use in stem cell mobilization in patients with Lymphoma or Multiple Myeloma. Drugs, 71, 1623-1647.
16. Kuittinen, T., Nousiainen, T., Halonen, P., Mahlamaki, E. & Jantunen, E. (2004) Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplantation, 33, 907-912.
17. Li, J., Hamilton, E., Vaughn, L., Graiser, M., Renfroe, H., Lechowicz, M.J., Langston, A., Prichard, J.M., Anderson, D., Gleason, C., Lonial, S., Flowers, C.R., Kaufman, J.L. & Waller, E.K. (2011) Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion, 51, 2175-2182.
18. McQuaker, I.G., Haynes, A.P., Stainer, C., Anderson, S. & Russell, N.H. (1997) Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. British Journal of Haematology, 98, 228-233.
19. Micallef, I.N., Sinha, S., Gastineau, D.A., Wolf, R., Inwards, D.J., Gertz, M.A., Hayman, S.R., Hogan, W.J., Johnston, P.B., Lacy, M.Q., Ansell, S.M., Buadi, F., Dingli, D., Dispenzieri, A., Litzow, M.R., Porrata, L.F., Winters, J.L. & Kumar, S. (2013) Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biology of Blood and Marrow Transplantation, 19, 87-93.
20. Milone, G., Leotta, S., Indelicato, F., Mercurio, S., Moschetti, G., Di Raimondo, F., Tornello, A., Consoli, U., Guido, G. & Giustolisi, R. (2003) G-CSF alone versus cyclophosphamide plus G-CSF in PBSC mobilization of patients with lymphoma: results depend on degree of previous pretreatment. Bone Marrow Transplantation, 31, 747-754.
21. Milone, G., Martino, M., Leotta, S., Guidi, S., Saccardi, R., Mercurio, S., Avola, G., Camuglia, M.G., Iacona, F., Bartolozzi, B., Nozzoli, C., Liggeri, S., Disca, S., Iacopino, L. & Bosi, A. (2012) CD34+ mobilization & pbsc apheretic harvest in multiple myeloma patients at first mobilization attempt: variability in results among different centers. Drugs and Cell Therapies in Hematology, Suppl n1, 2012, 91-103.
22. Milone, G., Tripepi, G., Martino, M., Ancora, F., Bartolozzi, B., Spadaro, A., Nozzoli, C., La Fauci, A., Amico, I., Leotta, S., Poidomani, M., Irrera, G., Iacopino, P., Saccardi, R. & Bosi, A. (2013) Early measurement of CD34+ in peripheral blood after cyclophosphamide and G-CSF predicts later CD34+ mobilization failure and can be used as criteria for testing "on demand" use of plerixafor. Blood Transfusion, 11, 94-101.
23. Olivieri, A., Marchetti, M., Lemoli, R., Tarella, C., Iacone, A., Lanza, F., Rambaldi, A. & Bosi, A. (2012) Proposed definition of poor mobilizer in lymphoma and multiple myeloma an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplantation, 47, 342-351.
24. Ozsan, G.H., Micallef, I.N., Dispenzieri, A., Kumar, S., Lacy, M.Q., Dingli, D., Hayman, S.R., Buadi, F.K., Wolf, R.C., Gastineau, D.A., Hogan, W.J. & Gertz, M.A. (2012) Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. American Journal of Hematology, 87, 1-4.
25. Pavone, V., Gaudio, F., Guarini, A., Perrone, T., Zonno, A., Curci, P. & Liso, V. (2002) Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or DHAP regimen plus G-CSF in non Hodgkin's lymphoma. Bone Marrow Transplantation, 29, 285-290.
26. Pusic, I., Jiang, S.Y., Landua, S., Uy, G.L., Rettig, M.P., Cashen, A.F., Westervelt, P., Vij, R., Abboud, C.N., Stockerl-Goldstein, K.E., Sempek, D.S., Smith, A.L. & DiPersio, J.F. (2008) Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation Biol Blood Marrow. Transplantation, 14, 1045-1056.
27. Seggewiss, R., Buss, E.C., Herrmann, D., Goldschmidt, H., Ho, A.D. & Freuhauf, S. (2003) Kinetics of peripheral blood stem cell mobilization following G-CSF supported Chemotherapy. Stem Cells, 21, 568-574.
28. Sinha, S., Gastineau, D., Micallef, I., Hogan, W., Ansell, S., Buadi, F., Dingli, D., Dispenzieri, A., Gertz, M., Greiner, C., Hayman, S., Inwards, D., Johnston, P., Lacy, M., Litzow, M., Porrata, L., Winters, J.L. & Kumar, S. (2011) Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplantation, 46, 943-949.
29. Smith, V.R., Popat, U., Ciurea, S., Nieto, Y., Anderlini, P., Rondon, G., Alousi, A., Qazilbash, M., Kebriaei, P., Khouri, I., de Lima, M., Champlin, R. & Hosing, C. (2013) Just-in-time rescue plerixafor in combination with chemotherapy & granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. American Journal of Hematology, doi: 10.1002/ajh.23499.
30. Stockerl-Goldstein, K.E., Reddy, S.A., Horning, S.F., Blume, K.G., Chao, N.F., Hu, W.W., Johnston, L.F., Long, G.D., Strober, S., Wong, R.M., Feiner, R.H., Kobler, S. & Negrin, R.S. (2000) Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. Biology of Blood and Marrow Transplantation, 6, 506-512.
31. Stroncek, D.F., Clay, M.E., Herr, G., Smith, J., Jaszcz, W.B., Ilstrup, S. & McCullough, J. (1997) The kinetics of G-CSF mobilization of CD34+ cells in healthy people. Transfusion Medicine, 7, 19-24.
32. Sugrue, M.W., Williams, K., Pollock, B.H., Khan, S., Peracha, S., Wingard, J.R. & Moreb, J.S. (2000) Characterization and outcome of "hard to mobilize"'lymphoma patients undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 39, 509-519.
33. Wuchter, P., Ran, D., Bruckner, T., Schmitt, T., Witzens-Harig, M., Neben, K., Goldschmidt, H. & Ho, A.D. (2010) Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biology of Blood and Marrow Transplantation, 16, 490-499.